11/17/2022 7:03:47 AM
Regeneron, CytomX Announce Strategic Research Collaboration In Field Of Conditional Bispecific Therapeutics For Cancer
11/9/2022 5:02:04 PM
Wedbush Is Increasing CytomX Therapeutics, Inc. (CTMX) FY23 Estimate To -1.30 From -1.37
11/9/2022 5:01:46 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) Q4 23 Estimate To -0.32 From -0.34
11/9/2022 5:01:37 PM
Wedbush Is Increasing CytomX Therapeutics, Inc. (CTMX) Q3 23 Estimate To -0.32 From -0.34
11/9/2022 5:01:25 PM
Wedbush Is Increasing CytomX Therapeutics, Inc. (CTMX) Q2 23 Estimate To -0.32 From -0.33
11/9/2022 5:01:09 PM
Wedbush Is Increasing CytomX Therapeutics, Inc. (CTMX) Q1 23 Estimate To -0.34 From -0.36
11/9/2022 5:00:53 PM
Wedbush Is Increasing CytomX Therapeutics, Inc. (CTMX) FY22 Estimate To -1.27 From -1.28
11/9/2022 5:00:39 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) Q4 22 Estimate To -0.18 From -0.20
11/9/2022 4:59:51 PM
Wedbush Reiterates CytomX Therapeutics, Inc. (CTMX) At Neutral With $2 Price Target
7/7/2022 9:34:41 AM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) FY22 Estimate To -1.42 From -1.37
7/7/2022 9:34:29 AM
Wedbush Is Cutting CytomX Therapeutics, Inc. (CTMX) Q4 22 Estimate To -0.37 From -0.32
7/7/2022 9:30:25 AM
Wedbush Cuts CytomX Therapeutics, Inc. (CTMX) To Neutral From Outperform With $2 Down From $6 Price Target
5/26/2022 8:27:02 AM
CytomX Therapeutics Doses First Patient With CX-904 In Phase 1 Study In Patients With Advanced Solid Tumors
5/10/2022 4:51:59 PM
Wedbush Is Lowering CytomX Therapeutics, Inc. (CTMX) FY22 Rev. Estimate To 71.1 M From 74.0 M
5/10/2022 4:51:35 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) FY22 Estimate To -1.37 From -1.75
5/10/2022 4:51:20 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) Q4 22 Estimate To -0.32 From -0.47
5/10/2022 4:50:37 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) Q3 22 Estimate To -0.35 From -0.45
5/10/2022 4:50:19 PM
Wedbush Is Raising CytomX Therapeutics, Inc. (CTMX) Q2 22 Estimate To -0.34 From -0.44
5/10/2022 4:49:55 PM
Wedbush Reiterates CytomX Therapeutics, Inc. (CTMX) At Outperform With $6 Down From $10 Price Target